The month of birth has a seasonal effect in Chinese patients with narcolepsy and cataplexy

Journal of Clinical Sleep Medicine, Ahead of Print.
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Authors: Source Type: research

Related Links:

CONCLUSION: The target engagement of enerisant was demonstrated in the brains of living human subjects. The occupancy of histamine H3 receptors by enerisant at 2 h can be predicted by applying the plasma concentration of enerisant to Hill's plot. The preliminary time-course investigation showed persistently high brain occupancy with high doses of enerisant despite the decreasing plasma concentration of the drug. Five milligrams or less dose would be appropriate for the treatment for narcolepsy with initially high occupancy allowing for effective treatment of narcolepsy, and then the occupancy level would be expected to dec...
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
This session aims to discern the differences in demographic, comorbidities, and hospital outcomes associated with narcolepsy in adolescents hospitalized for mood disorders.
Source: Journal of the American Academy of Child and Adolescent Psychiatry - Category: Psychiatry Authors: Tags: Sleep-Wake Disorders Source Type: research
The objectives of this presentation are as follows: 1) the attendee will describe the differential diagnosis for a youth presenting with excessive daytime sleepiness; 2) the attendee will recognize risk factors for obstructive sleep apnea (OSA) in youth and formulate a treatment plan; and 3) the attendee will outline the assessment of youth at risk for narcolepsy.
Source: Journal of the American Academy of Child and Adolescent Psychiatry - Category: Psychiatry Authors: Tags: Clinical Perspectives 27 Source Type: research
ConclusionPD individuals are more likely to experience EDS and fall asleep inappropriately during activities if DQB1*0602 positive. Genetic vulnerability may explain EDS risk in PD.
Source: Journal of Neurology - Category: Neurology Source Type: research
In conclusion, across three large clinical trials of participants with narcolepsy or obstructive sleep apnea, Epworth Sleepiness Scale scores demonstrated a robust acceptable level of test-retest reliability in evaluating treatment response over time.PMID:34545626 | DOI:10.1111/jsr.13476
Source: Journal of Sleep Research - Category: Sleep Medicine Authors: Source Type: research
Journal of Clinical Sleep Medicine, Ahead of Print.
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Authors: Source Type: research
Epilepsy Behav. 2021 Sep 14;124:108311. doi: 10.1016/j.yebeh.2021.108311. Online ahead of print.ABSTRACTExcessive daytime sleepiness (EDS) and attentional deficits are often observed in people with epilepsy. They may be the consequence of seizures and subclinical discharges as well as of comorbid conditions as obstructive sleep apnea/hypopnea syndrome (OSAS), attention deficit hyperactivity disorder (ADHD), or other less frequent disorders. Excessive daytime sleepiness may also be caused or worsened by antiseizure medications (ASMs). Several meta-analyses suggested that lamotrigine, lacosamide, and perhaps eslicarbazepine ...
Source: Epilepsy and Behaviour - Category: Neurology Authors: Source Type: research
ConclusionsMinimally important difference and clinically important response estimates for the FOSQ-10 for adults with excessive daytime sleepiness in narcolepsy or obstructive sleep apnea will be helpful for interpreting changes over time and defining a clinical responder.ClinicalTrials.gov identifiersNCT02348593 (first submitted January 15, 2015) and NCT02348606 (first submitted January 15, 2015)
Source: Sleep and Breathing - Category: Respiratory Medicine Source Type: research
Journal of Clinical Sleep Medicine, Ahead of Print.
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Authors: Source Type: research
In conclusion, pitolisant is a differentiated therapeutic option, when compared with psychostimulants, for the treatment of EDS, as this agent does not show any amphetamine-like properties within in vivo preclinical models.
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: China Health | Hospitals | Narcolepsy | Respiratory Medicine | Sleep Disorders | Sleep Medicine